Vardenafil 20 Mg

chloroquinechloroquine increases toxicity of vardenafil by QTc interval.

Frequently Asked Questions (FAQs)

Potential Interactions: What to Watch Out For:

chloroquine increases toxicity of vardenafil by QTc interval. cyclophosphamidecyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Product	Dosage	Quantity + Bonus	Price
Viagra Generic	200mg	180 + 10 Pills	277.56€ 264.34€	Buy
Kamagra Effervescent Tablets	100 mg	14 Pills	51.61€ 49.15€	Buy
Viagra Original	100mg	4 Pills	40.94€ 38.99€	Buy
Priligy Generic Dapoxetine	60mg	60 + 8 Pills	183.06€ 174.34€	Buy
Kamagra Soft Tabs	100 mg	180 + 8 Pills	425.45€ 405.19€	Buy
Kamagra Polo	100 mg	32 Pills	125.88€ 119.89€	Buy
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€	Buy
Levitra Original	20mg	48 + 4 Pills	235.14€ 223.94€	Buy
Kamagra Gold	100 mg	60 + 4 Pills	201.34€ 191.75€	Buy
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€	Buy
Apcalis SX Oral Jelly	20mg	30 + 5 Sachets	141.84€ 135.09€	Buy
Kamagra Gold	50 mg	120 + 6 Pills	281.13€ 267.74€	Buy

cyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil enhances blood flow to the penis.
• It is sold under brand names like Levitra and Staxyn.
• The drug is generally well-tolerated when used correctly.
• Common side effects include dizziness and nasal congestion.
• It should be stored in a cool, dry place away from children.
• Vardenafil is not an aphrodisiac; it requires sexual stimulation.
• Excessive doses can increase cardiovascular risks.
• It’s important to follow the doctor’s instructions for use.
• Patients with heart conditions should consult a doctor before use.
• Vardenafil may cause visual disturbances in some people.
• Regular medical review is recommended during treatment.

drospirenonedrospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme erectile dysfunction tablets uk CYP3A4 metabolism.

Available Strengths & Forms

drospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Vardenafil is sometimes used off-label for other circulatory issues.
• It is important to avoid using if you have a history of stroke.
• Consult your healthcare provider if you experience chest pain.
• Patients with ocular conditions should use caution.
• Vardenafil may cause a drop in blood pressure.
• The medication should be stored away from heat and moisture.
• It is safer to take Vardenafil under medical supervision.
• Lifelong medical monitoring may be required in some cases.
• Vardenafil is not suitable for men with certain heart conditions.
• Combining with nitrates can cause dangerous hypotension.
• Always read the medication guide before use.

labetalolvardenafil increases effects of labetalol by pharmacodynamic synergism.

Mechanism of Action

Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop.

4.1 Clinical Trial Evidence

Onset of Action:

vardenafil increases effects of labetalol by pharmacodynamic synergism.

Understanding Vardenafil: How It Works and Its Pharmacokinetics

chloroquinechloroquine increases toxicity of vardenafil by QTc interval. chloroquine increases toxicity of vardenafil by QTc interval. cyclophosphamidecyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. cyclophosphamide will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. drospirenonedrospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme erectile dysfunction tablets uk CYP3A4 metabolism.

Mechanism of Action:

drospirenone will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. labetalolvardenafil increases effects of labetalol by pharmacodynamic synergism. vardenafil increases effects of labetalol by pharmacodynamic synergism. Possible additive vasorelaxation, leading to low blood pressure. Soluble guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates A suitable time interval following PDE5 dosing for the safe administration of nitrates or nitric oxide donors has not been determined Use with caution in anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease), cardiovascular disease, left ventricular outflow obstruction, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, multidrug antihypertensive regimens, retinitis pigmentosa, concomitant use of CYP3A4 inhibitors, patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia) There have been rare reports of prolonged erections >4 hr and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil; in the event that an erection persists >4 hours, the patient should seek immediate medical assistance; if priapism is not treated immediately, penile tissue damage and permanent loss of potency may result Physicians should consider the cardiovascular status of their patients; there is a degree of cardiac risk associated with sexual activity; treatment for erectile dysfunction, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status Patients with left ventricular outflow obstruction, (for example, aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators including PDE5 inhibitors Until further information available, use is not recommended in unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within last 6 months); severe cardiac failure Consider counseling patients about protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV); drug offers no protection against sexually transmitted diseases Patients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Safety and efficacy of drug used in combination with other treatments for erectile dysfunction not studied; use of such combinations not recommended Vision loss may occur rarely and may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION); patient should seek medical assistance for sudden loss in one or both eyes; patients who have already experienced NAION are at increased risk of recurrence; use is not recommended in patients with known degenerative retinal disorders May increase risk of rare sudden vision loss attributed to nonarteritic ischemic optic neuropathy; if vision problems arise, discontinue, and contact physician The drug has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic); while this normally would be expected to be of little consequence in most patients, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects Physicians should advise patients to stop taking all PDE5 inhibitors, and seek prompt medical attention in event of sudden decrease or loss of hearing; these events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to intake of PDE5 inhibitors, including vardenafil; it is not possible to determine whether these events are related directly to use of PDE5 inhibitors or to other factors CYP3A4 inhibitorsConcomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitorsLong-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Concomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitors Long-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Alpha blockersCaution advised when PDE5 inhibitors co-administered with alpha-blockers; PDE5 inhibitors, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects; when vasodilators are used in combination, an additive effect on blood pressure may be anticipated; in some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (eg, fainting)Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor; patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitorsIn patients who are stable on alpha-blocker therapy, initiate PDE5 inhibitors at lowest recommended starting doseIn patients already taking optimized dose of PDE5 inhibitor, initiate alpha-blocker therapy at lowest dose; stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitorSafety of combined use of other PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs Caution advised when PDE5 inhibitors co-administered with alpha-blockers; PDE5 inhibitors, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects; when vasodilators are used in combination, an additive effect on blood pressure may be anticipated; in some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (eg, fainting) Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor; patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors In patients who are stable on alpha-blocker therapy, initiate PDE5 inhibitors at lowest recommended starting dose In patients already taking optimized dose of PDE5 inhibitor, initiate alpha-blocker therapy at lowest dose; stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitor Safety of combined use of other PDE5 inhibitors and alpha-blockers may be affected by other buy tadalista 60 variables, including intravascular volume depletion and other anti-hypertensive drugs QT prolonging drugsAvoid coadministration with drugs that have a high risk for QT prolonationPatients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Avoid coadministration with drugs that have a high risk for QT prolonation Patients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Controlled studies in pregnant women show no evidence of fetal risk.

Medical Professionals

Sexual stimulation causes nitric oxide to be released in corpus cavernosum, and nitric oxide activates guanylate cyclase, which in turn increases cyclic guanosine monophosphate (cGMP), thus causing smooth-muscle relaxation; PDE-5 inhibitors enhance smooth muscle-relaxing effects of nitric oxide in corpus cavernosum by inhibiting degradation of cGMP Peak plasma concentration: 8-19% lower for ODT than for film-coated tablet Metabolized in liver by CYP3A4 and (in minor amounts) CYP2C9 Metabolites: M1 (active; plasma concentration 26% of parent compound) Take about 60 minutes before sexual activity Maximum dosing frequency is one tablet per day Place on tongue where it will dissolve Adding plans allows you to compare formulary status to other drugs in the same class. To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. View the ed treatment drugs formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states. Possible additive vasorelaxation, leading to low blood pressure.

• Vardenafil may interact with medications for blood pressure.
• The drug is metabolized in the liver, caution in liver disease.
• Avoid excessive alcohol to reduce side effects.
• Do not take Vardenafil with other PDE5 inhibitors.
• It is important to stay calm and relaxed during use.
• Sexual health consultations can optimize treatment outcomes.
• Be aware of potential side effects and seek help if needed.
• Always check expiration date before use.
• It’s not a substitute for a healthy lifestyle.
• Use only as prescribed by your healthcare professional.
• Contact a doctor if Vardenafil does not work as expected.

Soluble guanylate cyclase (sGC) stimulators (eg, riociguat); concomitant use can cause hypotension Coadministration with nitrates (either regularly and/or intermittently) and nitric oxide donors Consistent with the effects of PDE5 inhibition on the nitric oxide/cyclic guanosine monophosphate pathway, PDE5 inhibitors may potentiate the hypotensive effects of nitrates A suitable time interval following PDE5 dosing for the safe administration of nitrates or nitric oxide donors has not been determined Use with caution in anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie’s disease), cardiovascular disease, left ventricular outflow obstruction, bleeding disorders, active peptic ulcer disease, liver disease, renal impairment, multidrug antihypertensive regimens, retinitis pigmentosa, concomitant use of CYP3A4 inhibitors, patients who have conditions that may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia) There have been rare reports of prolonged erections >4 hr and priapism (painful erections greater than 6 hours in duration) for this class of compounds, including vardenafil; in the event that an erection persists >4 hours, the patient should seek immediate medical assistance; if priapism is not treated immediately, penile tissue damage and permanent loss of potency may result Physicians should consider the cardiovascular status of their patients; there is a degree of cardiac risk associated with sexual activity; treatment for erectile dysfunction, should not be used in men for whom sexual activity is not recommended because of their underlying cardiovascular status Patients with left ventricular outflow obstruction, (for example, aortic stenosis and idiopathic hypertrophic subaortic stenosis) can be sensitive to the action of vasodilators including PDE5 inhibitors Until further information available, use is not recommended in unstable angina; hypotension (resting systolic blood pressure of <90 mmHg); uncontrolled hypertension (>170/110 mmHg); recent history of stroke, life-threatening arrhythmia, or myocardial infarction (within last 6 months); severe cardiac failure Consider counseling patients about protective measures necessary to guard against sexually transmitted diseases, including Human Immunodeficiency Virus (HIV); drug offers no protection against sexually transmitted diseases Patients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Safety and efficacy of drug used in combination with other treatments for erectile dysfunction not studied; use of such combinations not recommended Vision loss may occur rarely and may be a sign of non-arteritic anterior ischemic optic neuropathy (NAION); patient should seek medical assistance for sudden loss in one or both eyes; patients who have already experienced NAION are at increased risk of recurrence; use is not recommended in patients with known degenerative retinal disorders May increase risk of rare sudden vision loss attributed to nonarteritic ischemic optic neuropathy; if vision problems arise, discontinue, and contact physician The drug has systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 7 mmHg systolic and 8 mmHg diastolic); while this normally would be expected to be of little consequence in most patients, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects Physicians should advise patients to stop taking all PDE5 inhibitors, and seek prompt medical attention in event of sudden decrease or loss of hearing; these events, which may be accompanied by tinnitus and dizziness, have been reported in temporal association to intake of PDE5 inhibitors, including vardenafil; it is not possible to determine whether these events are related directly to use of PDE5 inhibitors or to other factors CYP3A4 inhibitorsConcomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitorsLong-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Concomitant administration with potent CYP3A4 inhibitors (eg, ritonavir, indinavir, cobicistat, ketoconazole) or moderate CYP3A4 inhibitors (eg, erythromycin) increases plasma concentrations of drug; dosage adjustment is necessary when drug is administered with certain CYP3A4 inhibitors Long-term safety information is not available on concomitant administration of drug with HIV protease inhibitors Alpha blockersCaution advised when PDE5 inhibitors co-administered with alpha-blockers; PDE5 inhibitors, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects; when vasodilators are used in combination, an additive effect on blood pressure may be anticipated; in some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (eg, fainting)Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor; patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitorsIn patients who are stable on alpha-blocker therapy, initiate PDE5 inhibitors at lowest recommended starting doseIn patients already taking optimized dose of PDE5 inhibitor, initiate alpha-blocker therapy at lowest dose; stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitorSafety of combined use of other PDE5 inhibitors and alpha-blockers may be affected by other variables, including intravascular volume depletion and other anti-hypertensive drugs Caution advised when PDE5 inhibitors co-administered with alpha-blockers; PDE5 inhibitors, and alpha-adrenergic blocking agents are both vasodilators with blood-pressure lowering effects; when vasodilators are used in combination, an additive effect on blood pressure may be anticipated; in some patients, concomitant use of these two drug classes can lower blood pressure significantly leading to symptomatic hypotension (eg, fainting) Patients should be stable on alpha-blocker therapy prior to initiating a PDE5 inhibitor; patients who demonstrate hemodynamic instability on alpha-blocker therapy alone are at increased risk of symptomatic hypotension with concomitant use of PDE5 inhibitors In patients who are stable on alpha-blocker therapy, initiate PDE5 inhibitors at lowest recommended starting dose In patients already taking optimized dose of PDE5 inhibitor, initiate alpha-blocker therapy at lowest dose; stepwise increase in alpha-blocker dose may be associated with further lowering of blood pressure in patients taking a PDE5 inhibitor Safety of combined use of other PDE5 inhibitors and alpha-blockers may be affected by other buy tadalista 60 variables, including intravascular volume depletion and other anti-hypertensive drugs QT prolonging drugsAvoid coadministration with drugs that have a high risk for QT prolonationPatients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Avoid coadministration with drugs that have a high risk for QT prolonation Patients taking Class 1A (eg, quinidine, procainamide) or Class III (eg, amiodarone, sotalol) antiarrhythmic medications or those with congenital QT prolongation, should avoid using drug Controlled studies in pregnant women show no evidence of fetal risk.

Advice	Explanation	Additional Notes
Take on an empty stomach or after light meal	Food, especially high-fat meals, can delay absorption	Best taken at least 30 minutes before sexual activity
Do not exceed prescribed dose	Risk of side effects or interactions	Follow healthcare provider guidance
Avoid alcohol consumption	Excessive alcohol can increase risk of side effects	Moderate intake may be acceptable
Report adverse effects promptly	Includes vision changes, prolonged erections, severe dizziness	Seek immediate medical help if needed

Sexual stimulation causes nitric oxide to be released in corpus cavernosum, and nitric oxide activates guanylate cyclase, which in turn increases cyclic guanosine monophosphate (cGMP), thus causing smooth-muscle relaxation; PDE-5 inhibitors enhance smooth muscle-relaxing effects of nitric oxide in corpus cavernosum by inhibiting degradation of cGMP Peak plasma concentration: 8-19% lower for ODT than for film-coated tablet Metabolized in liver by CYP3A4 and (in minor amounts) CYP2C9 Metabolites: M1 (active; plasma concentration 26% of parent compound) Take about 60 minutes before sexual activity Maximum dosing frequency is one tablet per day Place on tongue where it will dissolve Adding plans allows you to compare formulary status to other drugs in the same class. To view formulary information first create a list of plans. Your list will be saved and can be edited at any time. View the ed treatment drugs formulary and any restrictions for each plan. Manage and view all your plans together – even plans in different states.

• Vardenafil is a medication used to treat erectile dysfunction.
• It belongs to the class of PDE5 inhibitors.
• Typical adult dosage ranges from 5 to 20 mg.
• It is usually taken 30 to 60 minutes before activity.
• The medication's effects can last up to 4-6 hours.
• Vardenafil may cause side effects like headache or flushing.
• Alcohol consumption can increase side effects risk.
• It should not be used with nitrate drugs.
• Vardenafil is available by prescription only.
• It may interact with certain medications such as alpha-blockers.
• Proper dosing depends on medical history and response.

Compare formulary status to other drugs in the same class. Access your plan list on any device – mobile or desktop.

What special precautions should I follow?

Food and Diet:

Factors Accelerating or Delaying Effectiveness: